DUO ONCOLOGY INC
Founded 2020 · CIK 0001843372 · Biotech · Private
Ultrasmall nanomedicines (10-30nm) that co-deliver chemotherapy and immunotherapy to penetrate stroma-rich tumors
- Grants
- $850K
- 3 awards
- Sector median: 1
- Raised
- $4.2M
- 3 Form D · Jun 2025
- 16 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓202020212022202320242025
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $1,125,000 | |
| Private capital raised | Form D · SEC | $2,700,000 | |
| Federal grant | Department of Health and Human Services · Phase I · A novel dual-carrier ultrasmall nanomedicine for the treatment of stroma-rich pancreatic cancer | $394,967 | |
| Federal grant | Department of Health and Human Services · Phase I · A novel dual-carrier ultrasmall nanomedicine for the treatment of stroma-rich pancreatic cancer | $55,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Stroma-penetrating nanomedicine to improve treatment for pancreatic cancer | $399,970 | |
| Private capital raised | Form D · SEC | $400,000 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2507 | CONFLUENCE LIFE SCIENCES, INC. | — | $5.7M |
| 2508 | Panorama Medicine Inc | — | $4.7M |
| 2509 | GENEDIT INC | — | — |
| 2510 | DUO ONCOLOGY INC | — | $4.2M |
| 2511 | Synthekine | — | — |
| 2512 | Skyhawk Therapeutics | — | — |
| 2513 | Nouscom | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- ROBERT ASHLEYDirector
- KATHERINE EICHINGERExecutive Officer
- JOE GATTODirector
- JING-ZHOU HOUDirector · Executive Officer · Promoter
- SONG LIDirector · Promoter
- LUSONG LUODirector
- VICTORIA MANAXDirector
- STANLEY MARKSDirector
- SAM ROTHSTEINDirector · Executive Officer · Promoter
- JINGJING SUNPromoter
- STEPHEN THORNEDirector · Executive Officer · Promoter
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.